N
DFTX

Nuveen’s Definium Therapeutics DFTX Stock Holding History

Nuveen’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.2M Buy
698,130
+421,676
+153% +$7.16M ﹤0.01% 1393
2025
Q4 		$3.7M Buy
276,454
+42,950
+18% +$532K ﹤0.01% 2039
2025
Q3 		$2.75M Sell
233,504
-6,338
-3% -$59.1K ﹤0.01% 2164
2025
Q2 		$1.56M Sell
239,842
-26,209
-10% -$172K ﹤0.01% 2412
2025
Q1 		$1.56M Sell
266,051
-20,283
-7% -$145K ﹤0.01% 2445
2024
Q4 		$1.99M Buy
286,334
+8,856
+3% +$60.9K ﹤0.01% 2387
2024
Q3 		$1.58M Buy
277,478
+73,338
+36% +$510K ﹤0.01% 2537
2024
Q2 		$1.47M Buy
+204,140
New +$1.79M ﹤0.01% 2531

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nuveen's DFTX Position: Q1 2026 in Review

Nuveen increased its Definium Therapeutics (DFTX) stake by 153% in Q1 2026, buying an estimated $7.16M and bringing the position to 698,130 shares worth $13.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1393.

Nuveen first reported a position in DFTX in Q2 2024 and has held it in 8 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Nuveen held 698,130 shares of Definium Therapeutics worth $13.2M as of Q1 2026.
  • Nuveen bought 421,676 Definium Therapeutics shares in Q1 2026, an estimated $7.16M.
  • Definium Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1393 holding.
  • Nuveen first reported a position in Definium Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.